These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 12750235)

  • 1. Association of markers of insulin and glucose control with subsequent colorectal cancer risk.
    Saydah SH; Platz EA; Rifai N; Pollak MN; Brancati FL; Helzlsouer KJ
    Cancer Epidemiol Biomarkers Prev; 2003 May; 12(5):412-8. PubMed ID: 12750235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased peripheral blood mitochondrial DNA content is related to HbA1c, fasting plasma glucose level and age of onset in type 2 diabetes mellitus.
    Xu FX; Zhou X; Shen F; Pang R; Liu SM
    Diabet Med; 2012 Jul; 29(7):e47-54. PubMed ID: 22211946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
    Herz M; Johns D; Reviriego J; Grossman LD; Godin C; Duran S; Hawkins F; Lochnan H; Escobar-Jiménez F; Hardin PA; Konkoy CS; Tan MH
    Clin Ther; 2003 Apr; 25(4):1074-95. PubMed ID: 12809958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased blood glucose and insulin, body size, and incident colorectal cancer.
    Schoen RE; Tangen CM; Kuller LH; Burke GL; Cushman M; Tracy RP; Dobs A; Savage PJ
    J Natl Cancer Inst; 1999 Jul; 91(13):1147-54. PubMed ID: 10393723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised, controlled trial of self-monitoring of blood glucose in patients with type 2 diabetes receiving conventional insulin treatment.
    Nauck MA; Haastert B; Trautner C; Müller UA; Nauck MA; Heinemann L;
    Diabetologia; 2014 May; 57(5):868-77. PubMed ID: 24445534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic syndrome components and colorectal adenoma in the CLUE II cohort.
    Tsilidis KK; Brancati FL; Pollak MN; Rifai N; Clipp SL; Hoffman-Bolton J; Helzlsouer KJ; Platz EA
    Cancer Causes Control; 2010 Jan; 21(1):1-10. PubMed ID: 19774471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of glycaemic control in type 2 diabetes: favourable changes in blood pressure, total cholesterol and triglycerides, but not in HDL cholesterol, fibrinogen, Von Willebrand factor and (pro)insulin.
    Becker A; van der Does FE; van Hinsbergh VW; Heine RJ; Bouter LM; Stehouwer CD
    Neth J Med; 2003 Apr; 61(4):129-36. PubMed ID: 12852722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective study of plasma C-peptide and colorectal cancer risk in men.
    Ma J; Giovannucci E; Pollak M; Leavitt A; Tao Y; Gaziano JM; Stampfer MJ
    J Natl Cancer Inst; 2004 Apr; 96(7):546-53. PubMed ID: 15069117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of glycemia and other cardiovascular disease risk factors in older adults with type 2 diabetes mellitus: data from the Adult Diabetes Control and Management.
    Sazlina SG; Mastura I; Ahmad Z; Cheong AT; Adam BM; Jamaiyah H; Lee PY; Syed-Alwi SA; Chew BH; Sriwahyu T
    Geriatr Gerontol Int; 2014 Jan; 14(1):130-7. PubMed ID: 23581598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case-control study: the Japan public health center-based prospective study.
    Otani T; Iwasaki M; Sasazuki S; Inoue M; Tsugane S;
    Int J Cancer; 2007 May; 120(9):2007-12. PubMed ID: 17266031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing incident diabetes as defined by fasting plasma glucose or by HbA(1c). The AusDiab, Inter99 and DESIR studies.
    Soulimane S; Simon D; Shaw JE; Zimmet PZ; Vol S; Vistisen D; Magliano DJ; Borch-Johnsen K; Balkau B
    Diabet Med; 2011 Nov; 28(11):1311-8. PubMed ID: 21824186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
    Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
    Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gender difference in the association of insulin and the insulin-like growth factor axis with colorectal neoplasia.
    Yamaji T; Iwasaki M; Sasazuki S; Tsugane S
    Int J Obes (Lond); 2012 Mar; 36(3):440-7. PubMed ID: 21673650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential regulations of lipid profiles between Japanese responders and nonresponders treated with pioglitazone.
    Kutoh E
    Postgrad Med; 2011 Jan; 123(1):45-52. PubMed ID: 21293083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.
    Raskin P; Rendell M; Riddle MC; Dole JF; Freed MI; Rosenstock J;
    Diabetes Care; 2001 Jul; 24(7):1226-32. PubMed ID: 11423507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarker patterns of inflammatory and metabolic pathways are associated with risk of colorectal cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC).
    Aleksandrova K; Jenab M; Bueno-de-Mesquita HB; Fedirko V; Kaaks R; Lukanova A; van Duijnhoven FJ; Jansen E; Rinaldi S; Romieu I; Ferrari P; Murphy N; Gunter MJ; Riboli E; Westhpal S; Overvad K; Tjønneland A; Halkjær J; Boutron-Ruault MC; Dossus L; Racine A; Trichopoulou A; Bamia C; Orfanos P; Agnoli C; Palli D; Panico S; Tumino R; Vineis P; Peeters PH; Duell EJ; Molina-Montes E; Quirós JR; Dorronsoro M; Chirlaque MD; Barricarte A; Ljuslinder I; Palmqvist R; Travis RC; Khaw KT; Wareham N; Pischon T; Boeing H
    Eur J Epidemiol; 2014 Apr; 29(4):261-75. PubMed ID: 24791703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher morning to evening ratio in total dose of twice-daily biphasic insulin analog might be effective in achieving glucose control in patients with poorly controlled type 2 diabetes.
    Lee YH; Lee BW; Kwon HJ; Kang ES; Cha BS; Lee HC
    Diabetes Technol Ther; 2012 Jun; 14(6):508-14. PubMed ID: 22376081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women.
    Kaaks R; Toniolo P; Akhmedkhanov A; Lukanova A; Biessy C; Dechaud H; Rinaldi S; Zeleniuch-Jacquotte A; Shore RE; Riboli E
    J Natl Cancer Inst; 2000 Oct; 92(19):1592-600. PubMed ID: 11018095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
    Yki-Järvinen H; Dressler A; Ziemen M;
    Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
    Blonde L; Merilainen M; Karwe V; Raskin P;
    Diabetes Obes Metab; 2009 Jun; 11(6):623-31. PubMed ID: 19515182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.